Exclusive Summary

• Diprophylline Oral Solution, having passed consistency evaluation in China and classified as Class B in national medical insurance, directly addresses the vast global market for asthma and COPD.
• As a xanthine derivative, it retains clinical value and commercial opportunities in specific indications, market gaps, and regions where guidelines are not fully adopted.
• The product offers cost-effectiveness and its oral solution dosage form provides a differentiated advantage for specific patient populations, such as children and those with swallowing difficulties.

Asset Materials

Contact Us for Full Materials